La Monica, S.; Fumarola, C.; Cretella, D.; Bonelli, M.; Minari, R.; Cavazzoni, A.; Digiacomo, G.; Galetti, M.; Volta, F.; Mancini, M.;
et al. Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib. Cancers 2021, 13, 6.
https://doi.org/10.3390/cancers13010006
AMA Style
La Monica S, Fumarola C, Cretella D, Bonelli M, Minari R, Cavazzoni A, Digiacomo G, Galetti M, Volta F, Mancini M,
et al. Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib. Cancers. 2021; 13(1):6.
https://doi.org/10.3390/cancers13010006
Chicago/Turabian Style
La Monica, Silvia, Claudia Fumarola, Daniele Cretella, Mara Bonelli, Roberta Minari, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Francesco Volta, Maicol Mancini,
and et al. 2021. "Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib" Cancers 13, no. 1: 6.
https://doi.org/10.3390/cancers13010006
APA Style
La Monica, S., Fumarola, C., Cretella, D., Bonelli, M., Minari, R., Cavazzoni, A., Digiacomo, G., Galetti, M., Volta, F., Mancini, M., Petronini, P. G., Tiseo, M., & Alfieri, R.
(2021). Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib. Cancers, 13(1), 6.
https://doi.org/10.3390/cancers13010006
